Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide oral - Entera Bio

Next Previous
Drug Profile

Teriparatide oral - Entera Bio

Alternative Names: EB-612; EB-613; EBP-05; EP-101 - Entera Bio; hPTH(1-34); Oral hPTH(1-34); Oral PTH (1-34); oral PTH(1-34), teriparatide; Parathyroid hormone oral - Entera Bio; Parathyroid hormone-1-34 - Entera Bio; PTH oral - Entera Bio; PTH-1-34 - Entera Bio

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Entera Bio
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypoparathyroidism; Osteoporosis
  • Clinical Phase Unknown Stress fractures
  • Preclinical Non-union fracture

Most Recent Events

  • 27 Sep 2024 Pharmacokinetics and adverse events data from a phase II trial in Osteoporosis presented at the Annual Meeting of the American Society for Bone and Mineral Research 2024 (ASBMR-2024)
  • 07 Aug 2024 Clinical trials in Stress-fracture in Israel (unspecified route) prior to July 2024 (Entera Bio pipeline, July 2024)
  • 03 Jun 2024 Updated pharmacodynamics and adverse events data from the phase Ib trial in Hypoparathyroidism released by Entera Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top